1. Home
  2. AYTU vs PCLA Comparison

AYTU vs PCLA Comparison

Compare AYTU & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • PCLA
  • Stock Information
  • Founded
  • AYTU N/A
  • PCLA 2008
  • Country
  • AYTU United States
  • PCLA Japan
  • Employees
  • AYTU N/A
  • PCLA N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • PCLA Building Products
  • Sector
  • AYTU Health Care
  • PCLA Consumer Discretionary
  • Exchange
  • AYTU Nasdaq
  • PCLA Nasdaq
  • Market Cap
  • AYTU 19.7M
  • PCLA 16.9M
  • IPO Year
  • AYTU N/A
  • PCLA 2025
  • Fundamental
  • Price
  • AYTU $2.36
  • PCLA $0.54
  • Analyst Decision
  • AYTU Strong Buy
  • PCLA
  • Analyst Count
  • AYTU 2
  • PCLA 0
  • Target Price
  • AYTU $10.00
  • PCLA N/A
  • AVG Volume (30 Days)
  • AYTU 77.6K
  • PCLA 217.8K
  • Earning Date
  • AYTU 11-12-2025
  • PCLA 01-01-0001
  • Dividend Yield
  • AYTU N/A
  • PCLA N/A
  • EPS Growth
  • AYTU N/A
  • PCLA N/A
  • EPS
  • AYTU N/A
  • PCLA N/A
  • Revenue
  • AYTU $81,659,000.00
  • PCLA $5,475,228.00
  • Revenue This Year
  • AYTU N/A
  • PCLA N/A
  • Revenue Next Year
  • AYTU $2.00
  • PCLA N/A
  • P/E Ratio
  • AYTU $12.93
  • PCLA N/A
  • Revenue Growth
  • AYTU 0.41
  • PCLA 40.19
  • 52 Week Low
  • AYTU $0.95
  • PCLA $0.37
  • 52 Week High
  • AYTU $2.85
  • PCLA $9.80
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 55.26
  • PCLA 50.64
  • Support Level
  • AYTU $2.21
  • PCLA $0.42
  • Resistance Level
  • AYTU $2.38
  • PCLA $0.53
  • Average True Range (ATR)
  • AYTU 0.13
  • PCLA 0.04
  • MACD
  • AYTU 0.01
  • PCLA 0.03
  • Stochastic Oscillator
  • AYTU 73.08
  • PCLA 100.00

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

Share on Social Networks: